Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $178.71

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $178.71.

A number of equities analysts have weighed in on the stock. Raymond James reissued an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, December 19th. Piper Sandler decreased their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, UBS Group raised their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th.

Insider Activity

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. CIBC Asset Management Inc raised its stake in shares of Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after buying an additional 86 shares in the last quarter. EP Wealth Advisors LLC lifted its holdings in Sarepta Therapeutics by 2.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 16.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 155 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 2.7 %

SRPT opened at $124.49 on Wednesday. The firm has a market capitalization of $11.89 billion, a P/E ratio of 99.59 and a beta of 0.77. The firm’s 50 day moving average is $122.13 and its 200-day moving average is $131.40. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52-week low of $94.75 and a 52-week high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.